Prosecution Insights
Last updated: April 19, 2026
Application No. 18/043,971

PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE

Non-Final OA §103
Filed
Mar 03, 2023
Examiner
SEAMAN, D MARGARET M
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Loxo Oncology Inc.
OA Round
1 (Non-Final)
77%
Grant Probability
Favorable
1-2
OA Rounds
2y 4m
To Grant
84%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allow Rate
1063 granted / 1387 resolved
+16.6% vs TC avg
Moderate +8% lift
Without
With
+7.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
20 currently pending
Career history
1407
Total Applications
across all art units

Statute-Specific Performance

§101
3.7%
-36.3% vs TC avg
§103
15.1%
-24.9% vs TC avg
§102
24.3%
-15.7% vs TC avg
§112
33.9%
-6.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1387 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This application was filed 03/03/2023 and is a 371 of PCT/US2021/049621 (09/09/2021) which has PRO 63/076577 (09/10/2020). Claims 13, 17-18 and 20-34 have been canceled. Claims -12, 14-16 and 19 are before the Examiner. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim 19 is rejected under 35 U.S.C. 103 as being unpatentable over Xu and Zhang. Xu teaches compound 40 on page 3145 where the difference between compound 40 and the 7th compound of claim 19 is Cl vs Br. Xu teaches multiple halogens in the same position with no change in their position. Zhang teaches multiple compounds as herbicides such as #53 (where F is in the place of the instantly claimed Br) and #25 having Br in 3-position vs 4-position. Both of these compounds are herbicides and are made in the same process. It would have been obvious to one of ordinary skill in the art at the time of the invention to make the same compound with a different halogen with the reasonable expectation of getting a compound having the same or similar properties. Rationale: Both Xu and Zhang teach that various halogens can be in the same position on a compound all without changing the activity of the compound. Conclusion Claims 1-12 and 14-16 are allowed. Claim 19 is rejected. Any inquiry concerning this communication or earlier communications from the examiner should be directed to D MARGARET M SEAMAN whose telephone number is (571)272-0694. The examiner can normally be reached M-F 8am-4pm Eastern. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at 571-272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /D MARGARET M SEAMAN/Primary Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Mar 03, 2023
Application Filed
Oct 31, 2025
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599135
A COMPOSITION AND METHOD FOR PREPARING N-PHENYLPYRAZOLE-1-CARBOXAMIDES
2y 5m to grant Granted Apr 14, 2026
Patent 12595234
Bioactive Benzocycloheptene Analogues From Himachalenes and its Applications
2y 5m to grant Granted Apr 07, 2026
Patent 12595239
SUBSTITUTED ISOXAZOLINE DERIVATIVES
2y 5m to grant Granted Apr 07, 2026
Patent 12590072
THYROMIMETICS
2y 5m to grant Granted Mar 31, 2026
Patent 12577207
INDAZOLE DERIVATIVES AS CANNABINOID RECEPTOR PARTIAL AGONISTS
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
77%
Grant Probability
84%
With Interview (+7.9%)
2y 4m
Median Time to Grant
Low
PTA Risk
Based on 1387 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month